BUSPIRONE HYDROCHLORIDE EFFECTS ON HOSPITALIZATIONS FREQUENCY IN PATIENTS WITH CHRONIC HEART FAILURE AND MIXED ANXIETY-DEPRESSIVE DISORDER

Abstract

Aim. Assessing the impact of buspirone hydrochloride on hospitalizations frequency in patients with chronic heart failure (CHF) and mixed anxietydepressive disorder (MADD). Materials and methods. The study involved 49 patients with heart failure of ischemic etiology and MADD. Patients in Group 1 (n = 25) received buspirone hydrochloride (in the starting dose of 15 mg/day with a gradual (within 2 weeks) increasing to the effective (30 mg/day)) in addition to standard CHF therapy and coronary heart disease (CHD). Patients in group 2 (n = 24) received standard therapy of CHF and CHD. After 6 months, we evaluated hospitalizations frequency and duration in patients from both groups. Results. The risk of hospitalization for heart failure decompensation was significantly lower in patients from group 1 compared with patients from group 2 (HR 0.333, 95% CI 1,12-8,05, p = 0.035).Conclusions. Buspirone hydrochloride admission in addition to standard therapy is associated with reduced risk of hospitalization for decompensation of chronic heart failure in patients with MADD.

Keywords

• chronic heart failure
• mixed anxiety-depressive disorder
• decompensation
• hospitalization